Literature DB >> 21666188

Status of rubella and congenital rubella syndrome surveillance, 2005-2009, the World Health Organization European Region.

Laura A Zimmerman1, Mark Muscat, Dragan Jankovic, Ajay Goel, Henrik Bang, Nino Khetsuriani, Rebecca Martin.   

Abstract

BACKGROUND: The World Health Organization European Region has a goal for rubella elimination and congenital rubella syndrome (CRS) prevention. Although all Member States recommend a rubella-containing vaccine in their national immunization programs, rubella and CRS continue to occur, and surveillance quality varies throughout the region.
METHODS: To describe the status of regional rubella and CRS surveillance and assess progress toward elimination, we reviewed surveillance practices by surveying all 53 Member States and analyzed rubella and CRS surveillance data during 2005-2009.
RESULTS: Overall, 41 (91%) of 45 responding Member States have nationwide rubella surveillance, and 39 (87%) have nationwide CRS surveillance. During 2005-2009, rubella cases reported in the region decreased by 94% from 206,359 cases to 11,623 cases. The greatest decrease (99%) was observed in newly independent states of the former Soviet Union. In the rest of the region, high rubella incidence was observed in Poland, Romania, Italy, and San Marino during 2005-2008 and in Poland, Bosnia and Herzegovina, and Austria in 2009. A total of 68 CRS cases were reported during 2005-2009.
CONCLUSIONS: As the foundation to achieving and verifying rubella elimination, high-quality rubella and CRS surveillance needs to be implemented and sustained in all Member States. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.

Entities:  

Mesh:

Year:  2011        PMID: 21666188     DOI: 10.1093/infdis/jir104

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Authors:  Irene Barrabeig; Nuria Torner; Ana Martínez; Gloria Carmona; Pilar Ciruela; Joan Batalla; Josep Costa; Sergi Hernández; Luis Salleras; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-08       Impact factor: 3.452

3.  Trends of rubella incidence during a 5-year period of case based surveillance in Zimbabwe.

Authors:  Simbarashe Chimhuya; Portia Manangazira; Arnold Mukaratirwa; Pasipanodya Nziramasanga; Chipo Berejena; Annie Shonhai; Mary Kamupota; Regina Gerede; Mary Munyoro; Douglas Mangwanya; Christopher Tapfumaneyi; Charles Byabamazima; Eshetu Messeret Shibeshi; Kusum Jackison Nathoo
Journal:  BMC Public Health       Date:  2015-03-27       Impact factor: 3.295

Review 4.  Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review.

Authors:  Emilia Vynnycky; Elisabeth J Adams; Felicity T Cutts; Susan E Reef; Ann Marie Navar; Emily Simons; Lay-Myint Yoshida; David W J Brown; Charlotte Jackson; Peter M Strebel; Alya J Dabbagh
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

Review 5.  Strategies for elimination of rubella in pregnancy and of congenital rubella syndrome in high and upper-middle income countries.

Authors:  E Terracciano; F Amadori; V Pettinicchio; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2020-04-02

6.  Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.

Authors:  Stanley A Plotkin
Journal:  J Infect Dis       Date:  2021-09-30       Impact factor: 5.226

7.  Rubella immune status of neonates - a window towards seroprevalence among childbearing women.

Authors:  Iris Pejcic; Milica Rankovic Janevski; Aleksandra Knezevic; Djordje Jevtovic; Maja Stanojevic
Journal:  BMC Public Health       Date:  2016-08-19       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.